Related references
Note: Only part of the references are listed.18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study
Coreline N. Burggraaff et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma
Jakoba J. Eertink et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study
Lale Kostakoglu et al.
HAEMATOLOGICA (2022)
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index
N. George Mikhaeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S. Neelapu et al.
NATURE MEDICINE (2022)
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Mahmoud Elsawy et al.
BLOOD (2022)
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar et al.
LANCET (2022)
Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL
Peng Zhao et al.
ANNALS OF NUCLEAR MEDICINE (2021)
Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
A-S Cottereau et al.
ANNALS OF ONCOLOGY (2021)
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
Laetitia Vercellino et al.
BLOOD (2020)
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial
Heiko Schoder et al.
BLOOD (2020)
Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma
Hajira Ilyas et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial
Ulrich Duehrsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study
R. -O. Casasnovas et al.
BLOOD (2017)
Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL
N. George Mikhaeel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies
Michel Meignan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Christoph Mamot et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F] FDG PET to Predict Survival in Hodgkin Lymphoma
Salim Kanoun et al.
PLOS ONE (2015)
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus
Michel Meignan et al.
LEUKEMIA & LYMPHOMA (2012)
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma
Rene -Olivier Casasnovas et al.
BLOOD (2011)
Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma
Craig H. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy
Emmanuel Itti et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma
Malik E. Juweid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
